<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Immunotherapy on FinanClub</title>
    <link>https://finan.club/tags/immunotherapy/</link>
    <description>Recent content in Immunotherapy on FinanClub</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en-us</language>
    <lastBuildDate>Mon, 18 Dec 2023 09:05:43 +0000</lastBuildDate><atom:link href="https://finan.club/tags/immunotherapy/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>IBRX</title>
      <link>https://finan.club/us/ibrx/</link>
      <pubDate>Mon, 18 Dec 2023 09:05:43 +0000</pubDate>
      
      <guid>https://finan.club/us/ibrx/</guid>
      <description>score:697
Chances: ImmunityBio&amp;rsquo;s resubmission of its Biologics License Application for N-803 has been accepted for review by the FDA, indicating potential for approval of a promising treatment for bladder cancer. New data shows that ImmunityBio&amp;rsquo;s Memory Cytokine-Enriched Natural Killer cells may provide benefit to patients with small cell lung cancer and other types of neuroendocrine tumors, offering a positive outlook for the company&amp;rsquo;s therapies.</description>
    </item>
    
  </channel>
</rss>
